肝动脉化疗栓塞术联合自体DC-CIK细胞治疗BCLC C期肝癌的随机对照研究

Transarterial chemoembolization combined with autologous DC-CIK cells for the treatment of hepatocellular carcinoma of BCLC C-stage: a randomized controlled study

目的探讨肝动脉化疗栓塞(TACE)联合DC-CIK细胞治疗BCLC C期肝细胞癌的疗效。方法 60例BCLC C期HCC患者随机分为治疗组与对照组,治疗组患者采用TACE联合DC-CIK治疗,对照组患者只行TACE治疗,比较两组患者的免疫功能、半年和1年生存率。结果治疗组全血T细胞亚群CD3+CD8+明显升高,CD3+CD4+明显下降,较治疗前差异有统计学意义(P<0.05)。两组半年生存率分别为67.9%、48.1%(P<0.05),一年生存率分别为53.6%、29.6%(P<0.05)。结论 TACE联合DC-CIK细胞联合治疗比单纯TACE治疗效果更好,是BCLC C期肝细胞癌的一种有效的治疗方法 。

Objective To investigate the efficacy of transarterial chemoembolization （TACE） combined with autologous DC-CIK cells in treating hepatocellular carcinoma（HCC） of BCLC C-stage. Methods A total of 60 cases with HCC in BCLC C-stage were randomly and equally divided into the study group （n=30） and the control group （n=30）. TACE combined with autologous DC-CIK cells was employed in the patients of the study group, while only TACE was adopted in the patients of the control group. The immune function, six-month and one-year survival rates were determined, and the results were compared between the two groups. Results In the study group, the blood T lymphocyte subsets of CD3＋CD8＋ were significantly increased, while CD3＋CD4＋ were obviously decreased. When compared with the pretreatment levels, the differences were statistically significant （P〈0.05）. The six-month survival rate of the study group and the control group was 67.9% and 48.1% respectively （P〈0.05）, and the one-year survival rate of the study group and the control group was 53.6%and 29.6%respectively （P〈0.05）. Conclusion For the treatment of HCC in BCLC C-stage, the therapeutic effect of TACE combined with autologous DC-CIK cells is much better than that of pure TACE. Therefore, this therapy is an effective treatment for HCC in BCLC C-stage.